Payment overview · 2025
General Payments
$222.37
11 reported records · 8 companies
Healthcare provider profile · identity verified
James Arlin Stanley, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOUTH WILLIAMSON, KY · NPI 1568983195
Verified facts
What the public records show
CMS Open Payments records show James Arlin Stanley, APRN received $222.37 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.97 | 27.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.06 | 24.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.85 | 10.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.92 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.01 | 8.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.89 | 8.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.27 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.40 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.37 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.97 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.06 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 458 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 110 |
| Lisinopril | Lisinopril | 419 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 370 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 82 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 327 | 16 |
| Simvastatin | Simvastatin | 265 | 57 |
| Omeprazole | Omeprazole | 263 | 60 |
| Carvedilol | Carvedilol | 260 | 65 |
| Metformin Hcl | Metformin Hcl | 257 | 65 |
| Losartan Potassium | Losartan Potassium | 254 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 60 |
| Ezetimibe | Ezetimibe | 243 | 56 |
| Furosemide | Furosemide | 237 | 66 |
| Methylprednisolone | Methylprednisolone | 192 | 106 |
| Tramadol Hcl | Tramadol Hcl | 188 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 55 |
| Glipizide | Glipizide | 183 | 43 |
| Gabapentin | Gabapentin | 175 | 28 |
| Trazodone Hcl | Trazodone Hcl | 172 | 44 |
| Meloxicam | Meloxicam | 166 | 46 |
| Cephalexin | Cephalexin | 164 | 97 |
| Ropinirole Hcl | Ropinirole Hcl | 151 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 148 | 33 |
| Ibuprofen | Ibuprofen | 145 | 49 |
| Januvia | Sitagliptin Phosphate | 143 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 40 |
| Montelukast Sodium | Montelukast Sodium | 116 | 27 |
| Sertraline Hcl | Sertraline Hcl | 116 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 21 |
| Prednisone | Prednisone | 104 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 22 |
| Potassium Chloride | Potassium Chloride | 98 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 25 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 81 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 81 | 15 |
| Buspirone Hcl | Buspirone Hcl | 78 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 56 |
| Farxiga | Dapagliflozin Propanediol | 73 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 15 |
| Allopurinol | Allopurinol | 72 | 16 |
| Clonidine Hcl | Clonidine Hcl | 72 | 22 |
| Amoxicillin | Amoxicillin | 70 | 50 |
| Alendronate Sodium | Alendronate Sodium | 68 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 49 |
| Alprazolam | Alprazolam | 65 | suppressed |
| Celecoxib | Celecoxib | 65 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 20 |
| Lorazepam | Lorazepam | 62 | suppressed |
| Eliquis | Apixaban | 57 | suppressed |
| Sucralfate | Sucralfate | 56 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 54 | suppressed |
| Fluconazole | Fluconazole | 51 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Meclizine Hcl | Meclizine Hcl | 49 | 11 |
| Spironolactone | Spironolactone | 49 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 16 |
| Atenolol | Atenolol | 45 | 11 |
| Diazepam | Diazepam | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Levemir | Insulin Detemir | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 11 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | 12 |
| Cilostazol | Cilostazol | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Nystatin | Nystatin | 32 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 29 | suppressed |
| Ofloxacin | Ofloxacin | 29 | 22 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Azithromycin | Azithromycin | 24 | 15 |
| Brilinta | Ticagrelor | 24 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 13 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Oxaprozin | Oxaprozin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222.37 · 11 records | ABBVIE INC. | CAPLYTA, GVOKE HYPOPEN, Ozempic, QULIPTA, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error